Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 5

Due to the prevalence of chronic pain worldwide, there is an urgent need to improve pain management strategies. While opioid drugs have long been used to treat chronic pain, their use is severely limited by adverse effects and abuse liability. Neurostimulation techniques have emerged as a promising option for chronic pain that is refractory to other treatments. While different neurostimulation strategies have been applied to many neural structures implicated in pain processing, there is variability in efficacy between patients, underscoring the need to optimize neurostimulation techniques for use in pain management. This optimization requires a deeper understanding of the mechanisms underlying neurostimulation-induced pain relief. Here, we discuss the most commonly used neurostimulation techniques for treating chronic pain. We present evidence that neurostimulation-induced analgesia is in part driven by the release of endogenous opioids and that this endogenous opioid release is a common endpoint between different methods of neurostimulation. Finally, we introduce technological and clinical innovations that are being explored to optimize neurostimulation techniques for the treatment of pain, including multidisciplinary efforts between neuroscience research and clinical treatment that may refine the efficacy of neurostimulation based on its underlying mechanisms.

Over 20% of people worldwide suffer from chronic pain disorders (Goldberg and McGee, 2011). In response to an unmet need for effective pain management, opioid drugs have been widely adopted. Opioid drugs harness the body’s endogenous opioid receptors, which are dispersed throughout the central and peripheral nervous system to modulate pain perception. While prescription opioids often provide effective pain relief, they have undesirable and potentially dangerous side effects including abuse liability and respiratory depression. Their contribution to the ongoing opioid epidemic and the enormous negative impact of chronic pain underscore the need for safe and effective pain therapies (Manchikanti et al., 2012). Neurostimulation therapies are potential alternatives for managing medically refractory pain. However, these therapies are hampered by inconsistent pain relief across patients and diminishing analgesic effects over time (Kumar K. et al., 1998).

Read more | >

Birmingham scientists have identified an essential genetic code for a method called plasmid curing, which aims to “displace” antibiotic-resistance genes from bacteria.

Plasmids, which are small, circular strands of DNA, play a crucial role in allowing to share beneficial genes rapidly in a changing environment, most concerningly when they carry genes conferring resistance to antibiotics.

Professor Chris Thomas from Birmingham’s School of Biosciences has investigated plasmid curing for many years, and engineered useful “multi-copy” (many copies in each bacterium) plasmids for this purpose, resulting in a patented, efficient way to displace unwanted plasmids that carry resistance.

Read more | >

Investigating muscle activity and coactivation with surface electromyography (sEMG) gives insight into pathological muscle function during activities like walking in people with neuromuscular impairments, such as children with cerebral palsy (CP). There is large variation in the amount of coactivation reported during walking in children with CP, possibly due to the inconsistent handling of sEMG and in calculating the coactivation index. The aim of this study was to evaluate how different approaches of handling sEMG may affect the interpretation of muscle activity and coactivation, by looking at both absolute and normalized sEMG. Twenty-three ambulatory children with CP and 11 typically developing (TD) children participated. We conducted a three-dimensional gait analysis (3DGA) with concurrent sEMG measurements of tibialis anterior, soleus, gastrocnemius medialis, rectus femoris, and hamstring medialis. They walked barefoot at a self-selected, comfortable speed back and forth a 7-m walkway. The gait cycle extracted from the 3DGA was divided into six phases, and for each phase, root mean square sEMG amplitude was calculated (sEMG-RMS-abs), and also normalized to peak amplitude of the linear envelope (50-ms running RMS window) during the gait cycle (sEMG-RMS-norm). The coactivation index was calculated using sEMG-RMS-abs and sEMG-RMS-norm values and by using two different indices. Differences between TD children’s legs and the affected legs of children with CP were tested with a mixed model. The between-subject muscle activity variability was more evenly distributed using sEMG-RMS-norm; however, potential physiological variability was eliminated as a result of normalization. Differences between groups in one gait phase using sEMG-RMS-abs showed opposite differences in another phase using sEMG-RMS-norm for three of the five muscles investigated. The CP group showed an increased coactivation index in two out of three muscle pairs using sEMG-RMS-abs and in all three muscle pairs using sEMG-RMS-norm. These results were independent of index calculation method. Moreover, the increased coactivation indices could be explained by either reduced agonist activity or increased antagonist activity. Thus, differences in muscle activity and coactivation index between the groups change after normalization. However, because we do not know the truth, we cannot conclude whether to normalize and recommend incorporating both.

Surface electromyography (sEMG) is used to measure muscle activity and may be used clinically to investigate muscle function during activities such as walking in conditions affecting the neuromuscular system (1). In children with cerebral palsy (CP), three-dimensional gait analysis (3DGA) with simultaneous sEMG measurements is often conducted to get insight into muscle activity as part of treatment prescriptions and evaluation of treatment effect. Cerebral palsy, the most common cause of physical disability in childhood, is characterized by insufficient motor activity such as reduced muscle strength and poor balance, but also increased motor activity such as spasticity and excessive muscle coactivation (2, 3). Those features of children with CP may impair function in general and gait in particular. Compared to typically mature gait, children with CP have shown deviations in different gait phases and greater physiological variability during walking (4, 5).

Muscle coactivation, defined as simultaneous activity of agonist and antagonist muscles crossing the same joint, is a normal motor control strategy to increase joint stability and coordination (6, 7). During complex tasks, such as walking, coactivation occurs prominently at certain phases during the gait cycle, ensuring stability and allowing efficient walking. Excessive and/or prolonged coactivation, however, may cause inefficient movements by reducing flexibility and adaptability and increasing the loading of the joints, and thus, energy cost (6, 7, 9, 10). Therefore, a main treatment goal for ambulatory children with CP is to make walking easier, through, for example, normalizing altered muscle activity and coactivation (11). However, the role of the increased coactivation in children with CP has been questioned in several studies, and the findings are conflicting (9, 12–14).

Read more | >

A team of engineers at the University of California San Diego is making it easier for researchers from a broad range of backgrounds to understand how different species are evolutionarily related, and support the transformative biological and medical applications that rely on these species trees. The researchers developed a scalable, automated and user-friendly tool called ROADIES that allows scientists to infer species trees directly from raw genome data, with less reliance on the domain expertise and computational resources currently required.

Species trees are critical to solidifying our understanding of how species evolved on a broad scale, but can also help find functional regions of the genome that could serve as drug targets; link physical traits to genomic changes; predict and respond to zoonotic outbreaks; and even guide conservation efforts.

In a new paper published in the journal Proceedings of the National Academy of Sciences on May 2, the researchers, led by UC San Diego electrical and computer engineering professor Yatish Turakhia, showed that ROADIES infers species trees that are comparable in quality with the state-of-the-art studies, but in a fraction of the time and effort. This paper focused on four diverse life forms— , pomace flies, birds and budding yeasts—though ROADIES can be used for any species.

Read more | >

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 April 2025) approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients.

The subcutaneous formulation of nivolumab can be given as a 3–5-minute injection instead of the 30-or 60-minute intravenous (IV) infusion. Several common cancers can be treated by nivolumab, including lung, bowel, kidney, bladder, oesophageal, skin, and head and neck cancers.

Patient safety is our top priority, which is why I am pleased to confirm the national approval of the new under-the-skin injection version of nivolumab.

This approval marks an important step forward in improving treatment access and reducing the time patients spend in clinics. It has the potential to ease pressures on NHS services, while also giving patients flexibility in their care.

We’re assured that the appropriate regulatory standards of safety, quality, and efficacy for the approval of this new formulation have been met. As with all products, we will keep its safety under close review.

Read more | >

A decade ago, University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington’s disease?

They found that HTT is something like a traffic controller inside neurons, moving different cargo along neuronal highways called axons in concert with other proteins that are key for cellular function and survival. Reduce the amount of non-mutant HTT and you’ll create the neurological equivalent of traffic jams and roadblocks.

Now, the researchers have learned more about what can control the traffic-controlling HTT.

Read more | >

Thousands of patients will benefit from a new cancer jab for more than a dozen types of the disease, with the NHS the first in Europe to offer the new injection. The health service is rolling out an injectable form of immunotherapy, nivolumab, which means patients can receive their fortnightly or monthly treatment in 5 […]

Read more | >